Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2439801rdf:typepubmed:Citationlld:pubmed
pubmed-article:2439801lifeskim:mentionsumls-concept:C0330390lld:lifeskim
pubmed-article:2439801lifeskim:mentionsumls-concept:C0053799lld:lifeskim
pubmed-article:2439801pubmed:dateCreated1987-8-10lld:pubmed
pubmed-article:2439801pubmed:abstractTextIn an open study with 16 angina pectoris patients with concomitant chronic obstructive bronchitis, the effect of single oral doses of the beta-adrenoceptor antagonist bisoprolol (5, 10, 15, 20, 30, and 40 mg) on blood pressure (BP), heart rate (HR), airway resistance (AWR), and forced expiratory volume in 1 s (FEV1) was investigated. In the dose range between 5 and 20 mg, no increase in AWR and no decrease in FEV1 was observed. Thirty and 40 mg of bisoprolol produced an increase in AWR and a decrease in FEV1. A reduction in BP and HR was observed even after the lowest bisoprolol dose.lld:pubmed
pubmed-article:2439801pubmed:languageenglld:pubmed
pubmed-article:2439801pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2439801pubmed:citationSubsetIMlld:pubmed
pubmed-article:2439801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2439801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2439801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2439801pubmed:statusMEDLINElld:pubmed
pubmed-article:2439801pubmed:issn0160-2446lld:pubmed
pubmed-article:2439801pubmed:authorpubmed-author:DoronYYlld:pubmed
pubmed-article:2439801pubmed:issnTypePrintlld:pubmed
pubmed-article:2439801pubmed:volume8 Suppl 11lld:pubmed
pubmed-article:2439801pubmed:ownerNLMlld:pubmed
pubmed-article:2439801pubmed:authorsCompleteYlld:pubmed
pubmed-article:2439801pubmed:paginationS65-8lld:pubmed
pubmed-article:2439801pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:2439801pubmed:meshHeadingpubmed-meshheading:2439801-...lld:pubmed
pubmed-article:2439801pubmed:meshHeadingpubmed-meshheading:2439801-...lld:pubmed
pubmed-article:2439801pubmed:meshHeadingpubmed-meshheading:2439801-...lld:pubmed
pubmed-article:2439801pubmed:meshHeadingpubmed-meshheading:2439801-...lld:pubmed
pubmed-article:2439801pubmed:meshHeadingpubmed-meshheading:2439801-...lld:pubmed
pubmed-article:2439801pubmed:meshHeadingpubmed-meshheading:2439801-...lld:pubmed
pubmed-article:2439801pubmed:meshHeadingpubmed-meshheading:2439801-...lld:pubmed
pubmed-article:2439801pubmed:meshHeadingpubmed-meshheading:2439801-...lld:pubmed
pubmed-article:2439801pubmed:meshHeadingpubmed-meshheading:2439801-...lld:pubmed
pubmed-article:2439801pubmed:meshHeadingpubmed-meshheading:2439801-...lld:pubmed
pubmed-article:2439801pubmed:meshHeadingpubmed-meshheading:2439801-...lld:pubmed
pubmed-article:2439801pubmed:meshHeadingpubmed-meshheading:2439801-...lld:pubmed
pubmed-article:2439801pubmed:meshHeadingpubmed-meshheading:2439801-...lld:pubmed
pubmed-article:2439801pubmed:year1986lld:pubmed
pubmed-article:2439801pubmed:articleTitleBeta 1/beta 2-splitting of bisoprolol.lld:pubmed
pubmed-article:2439801pubmed:publicationTypeJournal Articlelld:pubmed